Zobrazeno 1 - 10
of 119
pro vyhledávání: '"Yuichi Baba"'
Autor:
Kenichiro Suwa, Yoshihisa Naruse, Takeru Nabeta, Takeshi Kitai, Tatsunori Taniguchi, Kenji Yoshioka, Hidekazu Tanaka, Takahiro Okumura, Yuichi Baba, Yuya Matsue, Yuichiro Maekawa
Publikováno v:
International Journal of Cardiology: Heart & Vasculature, Vol 53, Iss , Pp 101473- (2024)
Background: Nonsteroidal immunosuppressive therapy is a potential therapeutic strategy for cardiac sarcoidosis. However, it is not recommended as an established treatment option. This study aimed to demonstrate the clinical outcomes of patients with
Externí odkaz:
https://doaj.org/article/0a129e01aa5a4bcd84c69625c0870f52
Autor:
Yu Yamada, MD, Kimi Sato, MD, PhD, Masayoshi Yamamoto, MD, PhD, Takeru Nabeta, MD, PhD, Yoshihisa Naruse, MD, PhD, Tatsunori Taniguchi, MD, PhD, Takeshi Kitai, MD, PhD, Kenji Yoshioka, MD, PhD, Hidekazu Tanaka, MD, PhD, Takahiro Okumura, MD, PhD, Yuichi Baba, MD, PhD, Yudai Fujimoto, MD, Yuya Matsue, MD, PhD, Yuki Komatsu, MD, PhD, Akihiko Nogami, MD, PhD, Tomoko Ishizu, MD, PhD
Publikováno v:
JACC: Advances, Vol 3, Iss 8, Pp 101105- (2024)
Background: Ventricular arrhythmia (VA) is a life-threatening condition associated with cardiac sarcoidosis (CS). Right bundle branch block (RBBB) is a common conduction disorder in CS; however, its association with VA remains unknown. Objectives: Th
Externí odkaz:
https://doaj.org/article/9588a7f270114472bd281f05d1ce70c2
Autor:
Kei Kawada, Tomoaki Ishida, Hitoshi Fukuda, Yuki Hyohdoh, Toru Kubo, Tomoyuki Hamada, Yuichi Baba, Toshinobu Hayashi, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda, Hiroaki Kitaoka, Keisuke Ishizawa
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
IntroductionGuideline-directed medical therapy with renin-angiotensin system (RAS) inhibitors and beta-blockers has improved the survival of patients with heart failure (HF) and reduced left ventricular ejection fraction (HFrEF). However, it is uncle
Externí odkaz:
https://doaj.org/article/e34bac9ce74848e2895ccbfef15b579c
Autor:
Yuka Akama, Yudai Fujimoto, Yuya Matsue, Daichi Maeda, Kenji Yoshioka, Taishi Dotare, Tsutomu Sunayama, Takeru Nabeta, Yoshihisa Naruse, Takeshi Kitai, Tatsunori Taniguchi, Shuntaro Sato, Hidekazu Tanaka, Takahiro Okumura, Yuichi Baba, Tohru Minamino
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 6 (2024)
Background Current guidelines recommend placing an implantable cardiac defibrillator for patients with cardiac sarcoidosis and a severely impaired left ventricular ejection fraction (LVEF) of ≤35%. In this study, we determined the association betwe
Externí odkaz:
https://doaj.org/article/5f16d5f2cfae412f90228f48d0a24b89
Autor:
Takeru Nabeta, Shingo Matsumoto, Shunsuke Ishii, Yuko Eda, Mayu Yazaki, Teppei Fujita, Yuichiro Iida, Yuki Ikeda, Takeshi Kitai, Yoshihisa Naruse, Tatsunori Taniguchi, Kenji Yoshioka, Hidekazu Tanaka, Takahiro Okumura, Yuichi Baba, Yuya Matsue, Junya Ako
Publikováno v:
International Journal of Cardiology: Heart & Vasculature, Vol 50, Iss , Pp 101321- (2024)
Background: Clinical characteristics and the risk of cardiovascular events in patients with cardiac sarcoidosis (CS) according to the age of initial diagnosis are unclear. Methods: This study is a sub-analysis of the ILLUMINATE-CS registry, which is
Externí odkaz:
https://doaj.org/article/788997fe11f1494d98b07c2b88e7b833
Autor:
Kenta Sugiura, Toru Kubo, Yuri Ochi, Kazuya Miyagawa, Yuichi Baba, Tatsuya Noguchi, Takayoshi Hirota, Naohito Yamasaki, Yoshinori L. Doi, Hiroaki Kitaoka
Publikováno v:
ESC Heart Failure, Vol 9, Iss 4, Pp 2618-2625 (2022)
Abstract Aims We aim to clarify the prognosis on patients with hypertrophic cardiomyopathy (HCM) for a follow‐up period of more than 10 years. Methods and results We retrospectively analysed 102 consecutive patients with HCM diagnosed by 31 Decembe
Externí odkaz:
https://doaj.org/article/717c54cba80a4f55857fe6373b35acf1
Autor:
Toru Kubo, Yuichi Baba, Yuri Ochi, Takayoshi Hirota, Naohito Yamasaki, Kazuya Kawai, Katsuhito Yamamoto, Fumiaki Kondo, Kanji Bando, Eisuke Yamada, Takashi Furuno, Toshikazu Yabe, Yoshinori L. Doi, Hiroaki Kitaoka
Publikováno v:
ESC Heart Failure, Vol 8, Iss 6, Pp 5022-5030 (2021)
Abstract Aims There is limited information about the clinical significance of atrial fibrillation (AF), particularly new‐onset AF, in patients with hypertrophic cardiomyopathy (HCM) in a community‐based patient cohort. This study was carried out
Externí odkaz:
https://doaj.org/article/1c4b510648f84e658f0bdb2278c7577d
Autor:
Shota Miyakuni, Daichi Maeda, Yuya Matsue, Kenji Yoshioka, Taishi Dotare, Tsutomu Sunayama, Takeru Nabeta, Yoshihisa Naruse, Takeshi Kitai, Tatsunori Taniguchi, Hidekazu Tanaka, Takahiro Okumura, Yuichi Baba, Akihiko Matsumura, Tohru Minamino
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 24 (2022)
Background The prognostic role of BNP (B‐type natriuretic peptide) in patients with cardiac sarcoidosis without evident heart failure is unknown. Methods and Results This is a post hoc analysis of ILLUMINATE‐CS (Illustration of the Management and
Externí odkaz:
https://doaj.org/article/77a11c9bcc1e4f369dbbfd6bb0fccf5c
Autor:
Toru Kubo, Yuri Ochi, Yuichi Baba, Kenta Sugiura, Asa Takahashi, Takayoshi Hirota, Shigeo Yamanaka, Naohito Yamasaki, Yoshinori L. Doi, Hiroaki Kitaoka
Publikováno v:
ESC Heart Failure, Vol 7, Iss 6, Pp 3593-3600 (2020)
Abstract Aims Hypertrophic cardiomyopathy (HCM) is generally associated with mild disability and normal life expectancy. On the other hand, once the end‐stage phase of HCM characterized by left ventricular (LV) ejection fraction 1 year. HCM progres
Externí odkaz:
https://doaj.org/article/9f82aa7c2397407db474cc264fe09b32
Autor:
Briana K. Shimada, Naaiko Yorichika, Jason K. Higa, Yuichi Baba, Motoi Kobayashi, Toshinori Aoyagi, Tomohiro Suhara, Takashi Matsui
Publikováno v:
Physiological Reports, Vol 9, Iss 6, Pp n/a-n/a (2021)
Abstract The mechanistic target of rapamycin (mTOR) is a key mediator of energy metabolism, cell growth, and survival. While previous studies using transgenic mice with cardiac‐specific overexpression of mTOR (mTOR‐Tg) demonstrated the protective
Externí odkaz:
https://doaj.org/article/042ba68a7c4741258784f2e28684b7b3